Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1997-08-20
2000-12-26
Scheiner, Laurie
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4241841, 4241861, 435 693, 435 701, A61K 39193
Patent
active
061654779
ABSTRACT:
The Flaviviridae comprise a number of medically important pathogens that cause significant morbidity in humans including the dengue (DEN) virus, Japanese encephalitis (JE) virus, tick-borne encephalitis virus (TBE), and yellow fever virus (YF). Flaviviruses are generally transmitted to vertebrates by chronically infected mosquito or tick vectors. The viral particle which is enveloped by host cell membranes, comprises a single positive strand genomic RNA and the structural capsid (CA), membrane (M), and envelope (E) proteins. The E and M proteins are found on the surface of the virion where they are anchored in the membrane. Mature E is glycosylated and contains functional domains responsible for cell surface attachment and intraendosomal fusion activities. Problems have arisen in the art with respect to producing recombinant forms of the E glycoprotein that retain their native configuration and attendant properties associated therewith (i.e., ability to induce neutralizing antibody responses). To date, recombinantly produced E glycoproteins have suffered from a number of limitations including improper glycosylation, folding, and disulfide bond formation. The claimed invention has addressed these concerns by providing secreted recombinant forms of the E glycoprotein that are highly immunogenic and appear to retain their native configuration. Carboxy-terminally truncated forms of E containing the amino terminal 395 amino acids and a suitable secretion signal sequence were generated in Drosophila melanogaster Schneider cell lines. Immunogenic compositions comprising these recombinant envelope glycoproteins were capable of inducing protective, neutralizing antibody responses when administered to a suitable host.
REFERENCES:
patent: 5494671 (1996-02-01), Lai et al.
patent: 5514375 (1996-05-01), Paoletti et al.
Harlow, E., et al., 1988, "Immunizations", in Antibodies: A Laboratory Manual, Harlow, E., et al., eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 53-137.
Monath et al., "Flaviviruses," in Fields Virology, Third Edition, Fields et al., eds., Lippincott-Raven Publishers, Philadelphia, pp. 961-977 and 1002-1004, 1996.
Schlesinger et al., "New approaches to flavivirus vaccine development," Biotech. 20:289-307, 1992.
Stephenson, J., "Flavivirus vaccines," Vaccine 6:471-480, 1988.
Rico-Hesse et al., "Molecular evolution of dengue type 2 virus in thailand," Am. J. Trop. Med. Hyg. 58(1):96-101, 1998.
Igarashi, A., "Impact of dengue virus infection and its control," FEMS Immunol. Med. Microbiol. 18:291-300, 1997.
Bancroft, W., "Current status of dengue vaccines and prospects for the future," PRHSJ 6(1):23-26, 1987.
Culp et al., "Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in drosophila schneider cells," Biotech. 9:173-177, 1991.
de Oliveira et al., "Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B-and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application," Vaccine 12(11):1012-1017, 1994.
Delenda et al., "Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells," Arch. Virol. 139(1-2):197-207, 1994(a).
Delenda et al., "Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice," J. Gen. Virol. 75:1569-1578, 1994(b).
Nowak, T. and Wengler, G., "Analysis of Disulfides Present in the Membrane Proteins of the West Nile Flavivirus," Virology (1987) 156:127-137.
Putnak, R.A., "Progress in the Development of Recombinant Vaccines Against Dengue and Other Arthopod-borne Flaviviruses," Modern Vaccinology, E. Kurstak, ed. New York: Plenum Medical, 1994, chapter 11, 231-252.
Roehrig et al., "Mapping of Biologically Active Helper T-cell Epitopes on the Flavivirus Envelope Glycoprotein," Vaccines 92, Cold Spring Harbor Laboratory Press, 1992, p. 277-281.
Srivastava, A.K. et al., "Immunogenicity of Peptides Cleaved by Cyanogen Bromide from Japanese Encephalitis Virus Envelope Glycoprotein E," Acta Virol (1990) 34:228-238.
Srivastava, A.K. et al., "Japanese Encephalitis Virus Fusion Protein with Protein A Expressed in Escherichia coli Confers Protective Immunity in Mice," Microbiol Immunol (1991) 35:863-870.
Trirawatanapong, T. et al., "Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody," Gene (1992) 116:139-150.
Brandt, E.E., "Development of Dengue and Japanese Encephilitis Vaccines,"J. Infect Disease (1990) 162:577-583.
Chambers, T.J. et al., "Flavivirus Genome Organization, Expression and Replication," Annual Rev Microbiol (1990) 44:649-688.
Hahn, Y.S. et al., "Nucleotide Sequence of Dengue 2 RNA and Comparison of the Encoded Proteins with Those of Other Flaviviruses," Virology (1988) 162:167-180.
Halstead, S.B., "Pathogenesis of Dengue: Challenges to Molecular Biology," Science (1988) 239:476-481.
Henchal, E.A. and Putnak, J.R., "The Dengue Viruses," Clin Microbiol Rev. (1990) 3:376-396.
Jan, L., et al., "Increased Immunogenicity and Protective Efficacy in Outbread and Inbread Mice by Strategic Carboxyl-Terminal Truncation of Japanese Encephalitis Virus Envelope Glycoprotein," Am. J. Trop. Med. Hyg., 48(3), (1993) pp. 412-423.
Mandl, C.W. et al., "Antigenic Structure of the Flavivirus Envelope Protein E at the Molecular Level, Using Tick-Borne Encephalitis Virus as a Model," Virology (1989) 63:564-571.
Mason, P.W. et al., "The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coli," J. Gen. Virol (1990) 71:2107-2114.
Mason, P.W., et al., "Molecular Characterization of a Neutralizing Domain of the Japanese Encephilitis Virus Structural Glycoprotein," J. Gen Virol (1989) 70:2037-2048.
Megret, F. et al., "Use of Recombinant Fusion Proteins and Monoclonal Antibodies to Define Linear and Discontinuous Antigenic Sites on the Dengue Virus Envelope Gylcoprotein," Virlogy (1992) 187:480-491.
Men, R. et al., "Carboxy-Terminally Truncated Dengue Virus Envelope Glycoproteins Expressed on the Cell Surface and Secreted Extracellularly Exhibit Increased Immunogenicity in Mice," J. Virol (1991) 65:1400-1407.
Winkler, G. et al., "Characterization of a Disulphide Bridge-stabilized Antigenic Domain of Tick-borne Encephalitis Virus Structural Glycoprotein," J. Gen Virol (1987) 68:2239-2244.
Control of Virus Disease, Second Edition 1993.
Clements David
Ivy John
Nakano Eilen
Hawaii Biotechnology Group, Inc.
Parkin Jeffrey S.
Scheiner Laurie
LandOfFree
Subunit immonogenic composition against dengue infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Subunit immonogenic composition against dengue infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Subunit immonogenic composition against dengue infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-991782